Gail S. Page

About

Gail has over 30 years of experience in the healthcare industry. She was previously the CEO & President of Vermillion Inc., a leading diagnostics company focused on the development and commercialization of novel multi-proteomics tests. There, Gail forged a partnership with Quest Diagnostics and oversaw the commercial launch of the first FDA-cleared blood test to help diagnose ovarian cancer. Prior to her role at Vermillion, she served on the Executive Management team at Laboratory Corporation of America (NASDAQ: LH), one of the world’s leading diagnostic companies. Her current board appointments include Sword Diagnostics, Inc., NxPrenatal, Inc., and Chembio (NASDAQ: CEMI). In August of 2018, she was appointed as the Chief Business Advisor for the Dell Medical School Catalyst/UT Board. Gail earned a B.S. from the University of Florida and completed an executive management program at the Northwestern University Kellogg School of Management.

Source (opens in a new tab)